DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1956)

Obesity/Overweight | Landscape & Forecast | Disease Landscape & Forecast

Obesity/Overweight | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Obesity is a significant public health concern in the G7 countries and is growing as an epidemic. The body of evidence highlighting the physical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, few drug treatments are available, especially in Europe and Japan. Compounding this problem is the fact that available treatments do not have desirable risk-benefit profiles at low prices; in addition, few novel agents are in development for obesity. Consequently, there is a huge market opportunity for an antiobesity drug that elicits sustained weight loss and is safe, well tolerated, and affordable. However, such is the prevalence of obesity that, even if such an agent is developed and approved, payers will likely need to control access to it to limit the impact on finite healthcare budgets.

Questions Answered:

  • Which metabolic and central pathways have high potential as drug targets?
  • What is the prevalence of obesity in the major pharmaceutical markets under study?
  • How is obesity currently treated? What do experts think about Novo Nordisk’s Saxenda as a treatment for obese/overweight patients?
  • What is the current level of unmet need according to obesity experts? How will this need be addressed over the 2018-2028 forecast period?
  • What is the commercial potential of emerging therapies? How do leaders in the field of obesity management rate these drug candidates?
  • How will the obesity market evolve over the next ten years?

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • March 2019
      • October 2017
    • Executive Summary
      • Key Findings
    • Market Outlook
      • Key Findings
        • Expert Insight
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Obesity?
        • What Factors Are Constraining the Market for Obesity?
      • Drug-Class-Specific Trends
        • Fixed-Dose Combinations
        • Serotonin Receptor Agonists
        • Noradrenergic Anorectic Agents
        • GLP-1 Receptor Agonists
        • Lipase Inhibitors
        • Off-Label Prescription Drugs
    • Forecast
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Expert Insight
        • Disease Overview
      • Etiology
      • Pathophysiology
      • Natural History
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Key Findings
        • Expert Insight
      • Epidemiology Populations
        • Total Prevalence of Obesity and Overweight
        • Obesity Subtypes by Disease Severity
        • Drug-Treatable Overweight Cases
        • Diagnosed Prevalent Cases of Obesity and Overweight
        • Drug-Treated Prevalent Cases of Obesity and Overweight
    • Current Treatment Overview
      • Key Findings
        • Expert Insight
      • Treatment Goals
        • Physician Insights on Clinical End Points
      • Key Current Therapies
        • Overview
        • Lipase Inhibitors
        • Noradrenergic Anorectic Agents
        • Serotonin Receptor Agonists
        • GLP-1 Receptor Agonists
        • Fixed-Dose Combinations
        • Off-Label Prescription Drugs
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Drug Selection
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Key Findings
        • Expert Insight
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in Obesity
        • Future Attainment of Unmet Needs in Obesity
    • Emerging Therapies Overview
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Obesity
        • GLP-1 Receptor Agonists
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Obesity
      • Key Discontinuations and Failures in Obesity/Overweight
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Obesity Bibliography

Already a Client? Log in to access this report.

  • Pub Date: March 2019
  • Author(s): Andrew Frost; Sunali D. Goonesekera, SM; Rameshwar Prajapati, Ph.D., M.S. (Pharm.)
  • Andrew Frost is a Business Insights Analyst in Decision Resources Group’s Cardiovascular, Metabolic, Renal, and Hematologic Disorders team focusing on obesity and non-alcoholic steatohepatitis (NASH). In this role, he evaluates the latest primary and secondary research, as well as available commercial information, to forecast the potential of developmental drugs and provide insight on the various dynamics affecting relevant markets. Prior to joining DRG, Andrew worked as a Senior Drug Analyst at Citeline in the Cardiovascular and Metabolic Team. Andrew holds a BSc (Hons) degree in Pharmacology, awarded by King’s College London, and he has previously worked in the Immunopharmacology team at UCB.  

  • Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.

  • Rameshwar Prajapati, (Pharm.), is an Associate Analyst in Decision Resources Group’s cardiovascular, metabolic, renal, and hematologic disorders team, focusing primarily on metabolic and renal diseases. In this role, his main function is to perform primary and secondary research across the team’s range of therapeutic indications and provide insights and assessments for related pharmaceutical ; Rameshwar holds a bachelor’s degree in pharmacy from Dr. Gour University, Sagar, India. He obtained his master’s and doctorate degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Nagar, India. Rameshwar also received a German Academic Exchange Service (DAAD) fellowship to conduct his research on P-glycoprotein at the University of Bonn, ;

Purchase Report

Recent reports:
You may also be interested in: